×
Purple Biotech Total Long Term Liabilities 2014-2024 | PPBT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Purple Biotech total long term liabilities from 2014 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
View More
Purple Biotech Total Long Term Liabilities 2014-2024 | PPBT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Purple Biotech total long term liabilities from 2014 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.8B
Vertex Pharmaceuticals (VRTX)
$117.5B
Regeneron Pharmaceuticals (REGN)
$111.6B
Bristol Myers Squibb (BMY)
$109.4B
Gilead Sciences (GILD)
$105.3B
CSL (CSLLY)
$95.7B
GSK (GSK)
$80.5B
Alnylam Pharmaceuticals (ALNY)
$34.4B
Argenex SE (ARGX)
$31.7B
BioNTech SE (BNTX)
$29.2B
Biogen (BIIB)
$27B
BeiGene (BGNE)
$23.9B
Moderna (MRNA)
$23.1B
Illumina (ILMN)
$22.5B
Genmab (GMAB)
$15.5B
BioMarin Pharmaceutical (BMRN)
$13.2B
Incyte (INCY)
$13B
Exact Sciences (EXAS)
$12.6B
Vaxcyte (PCVX)
$12.4B
Insmed (INSM)
$12.4B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.5B
QIAGEN (QGEN)
$9.9B
Bio-Rad Laboratories (BIO.B)
$9.3B
Legend Biotech (LEGN)
$8.9B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$8.3B
Revolution Medicines (RVMD)
$7.9B
Intra-Cellular Therapies (ITCI)
$7.7B
Repligen (RGEN)
$7.7B